格列美脲治疗肥胖2型糖尿病的临床观察

目的观察肥胖T2DM患者联合应用格列美脲的临床疗效。方法选取76例血糖控制不佳的肥胖T2DM患者随机分为对照组和治疗组（联用格列美脲），进行12周临床观察。结果两组平均HbA1c及空腹血糖、餐后血糖均显著下降，治疗组下降更为显著；治疗组空腹胰岛素（Fins）和HO—MA-IR较治疗前下降，体重、BMI及胰岛素用量均显著减少；治疗组有1例患者发生一般性低血糖事件1次，无其他不良反应。结论对于血糖控制不佳的肥胖T2DM患者早期联用格列美脲，可有效降低患者空腹血糖及餐后血糖水平，有利于患者实现HbA1c达标；同时可显著降低胰岛素用量，提高治疗安全性和耐受性。

The clinical efficacy of glimepiride treatment of obese type 2 diabetes mellitus

Objective To observe the clinical efficacy of adding glimepiride versus placebo to previous antidiabetic regionen in obese type 2 diabetic patients . Methods 76 obese type 2 diabetic patients inadequately controlled were given either control group or therapy group （combination with glimepiride） for 12 weeks. Results HbA1 c levels and blood glucose of each group were significantly decreased. Moreover , there was significant decrease in the levels of fasting insulin , HOMA-IR , BMI and daily insulin dose in the therapy group versus the control group （all P〈0. 05 or 〈0. 01）. The number of hypoglycemic episodes was only once in therapy group. Conclusions Adding glimpiride versus placebo to the previous antidiabetic regimen is efficient and safe with decreased insulin dosage in obese type 2 diabetic patients.